Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRIKE: T2T vs SOC in Early Axial Spondyloarthritis
NCT02897115Phase 4Terminated
- Sponsor
- AbbVie Inc.
- Start
- Sep 2016
- Primary completion
- Dec 2017
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 4 trial of adalimumab in axial spondyloarthritis (axSpA), sponsored by AbbVie Inc.. Started Sep 2016; status: terminated.
02
Drugs
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on NCT02897115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02897115.